Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study
Therapeutic Advances in Psychopharmacology · 2026-04 · 16
DOI: 10.1177/20451253261437597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Psychopharmacology, online erschienen am 20.04.2026. Verfasst von Alessandro Cuomo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Depression
Abstract (Originalsprache)
Background
Treatment-resistant depression (TRD) remains a major clinical challenge, and long-term real-world data on intranasal esketamine are limited.
Objectives
To describe long-term dosing patterns and clinical outcomes associated with intranasal esketamine in routine clinical practice.
Design
Single-center observational cohort study with descriptive analyses.
Methods
We analyzed 45 patients with TRD treated with intranasal esketamine in a naturalistic setting, with follow-up extending up to 260 weeks. Esketamine was used adjunctively with ongoing oral antidepressants. Outcomes included the Montgomery–Åsberg Depression Rating Scale (MADRS), the Young Mania Rating Scale (YMRS), and the Glasgow Antipsychotic Side-effect Scale (GASS). Treatment patterns were summarized using person-time (person-weeks).
Results
Baseline MADRS was 40.0 (SD 4.63). Mean MADRS decreased to 22.9 (SD 7.99) at week 4 and to 9.70 (SD 5.35) at week 52, with mean scores remaining around 9–10 at later time points among patients with available follow-up. Eight patients (17.8%) discontinued treatment (lack of efficacy n = 4; intolerable adverse effects n = 3; lost to follow-up n = 1). No treatment-emergent hypomania or manic symptoms were observed; YMRS scores decreased over time. GASS scores were low overall, with median values of 0 from week 13 onwards.
Conclusion
In a real-world TRD cohort with complex comorbidities, intranasal esketamine used adjunctively was associated with sustained symptom improvement and a favorable long-term safety profile among patients who continued treatment, with dosing evolving from induction to individualized maintenance schedules. Findings are limited by the observational design, concomitant treatments, and survivor bias.
Trial registration
Not applicable.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada.
- Division of Psychiatry, Department of Molecular Medicine, University of Siena, Siena, Italy.
ORCID-Profile: Alessandro Cuomo, Roger McIntyre
Zitieren
APA
Cuomo, A., McIntyre, R., Koukouna, D., Pinzi, M., Pardossi, S., Firenzuoli, B., Barillà, G., Carmellini, P., Alamia, A., & Fagiolini, A. (2026). Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study. Therapeutic Advances in Psychopharmacology, 16. https://doi.org/10.1177/20451253261437597
Vancouver
Cuomo A, McIntyre R, Koukouna D, Pinzi M, Pardossi S, Firenzuoli B, et al. Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study. Therapeutic Advances in Psychopharmacology. 2026;16. doi:10.1177/20451253261437597
BibTeX
@article{Cuomo2026,
author = {Cuomo, Alessandro and McIntyre, Roger and Koukouna, Despoina and Pinzi, Mario and Pardossi, Simone and Firenzuoli, Bernardo and Barillà, Giovanni and Carmellini, Pietro and Alamia, Alberto and Fagiolini, Andrea},
title = {Intranasal esketamine in treatment-resistant depression: long-term dosing patterns and clinical outcomes in a 5-year observational study},
journal = {Therapeutic Advances in Psychopharmacology},
year = {2026},
volume = {16},
doi = {10.1177/20451253261437597}
}
EUVIMED